Anti-EGFR [EGFR1]

Tool Details

*FOR RESEARCH USE ONLY

• Name: Anti-EGFR [EGFR1]
• Clone: rEGFR1
• Tool sub type: Primary antibody
• Class: Recombinant
• Conjugation: Unconjugated
• Molecular weight: 175 kDa
• Reactivity: Human
• Host: Mouse
• Application: FACS ; IHC ; IF ; IP ; WB
• Description: Recombinant antibody which binds EGFR1 tyrosine kinase, commonly mutated in a range of cancers. Background and Research Application The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). EGFR activation signals multiple downstream signalling cascade pathways such as the Ras - ERK, PI3-K - Akt, Jak - STAT and PKC pathways which help in growth and proliferation of cells. Dysregulation of EGFR signalling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers, including head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, oesophagus, stomach and in squamous cell carcinoma. Tumours become dependent on EGFR signalling to maintain their malignant phenotypes. This is a recombinant version of the anti-EGFR1 monoclonal antibody.
• Immunogen: Human epidermoid carcinoma line A431
• Immunogen uniprot id: P00533
• Isotype: IgG2b

Target Details

• Target: Epidermal Growth Factor Receptor (EGFR, Her1)
• Molecular weight: 175 kDa
• Target background: Recombinant antibody which binds EGFR1 tyrosine kinase, commonly mutated in a range of cancers. Background and Research Application The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). EGFR activation signals multiple downstream signalling cascade pathways such as the Ras - ERK, PI3-K - Akt, Jak - STAT and PKC pathways which help in growth and proliferation of cells. Dysregulation of EGFR signalling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers, including head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, oesophagus, stomach and in squamous cell carcinoma. Tumours become dependent on EGFR signalling to maintain their malignant phenotypes. This is a recombinant version of the anti-EGFR1 monoclonal antibody.

Applications

• Application: FACS ; IHC ; IF ; IP ; WB

Handling

• Format: Liquid
• Concentration: 1 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS only
• Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
• Shipping conditions: Shipping at 4° C

Related Tools

• Related tools: Anti-EGFR [EGFR1]

References

• Original hybridoma first published in Waterfield et al. 1982. J Cell Biochem. 20(2):149-61. PMID: 6188757.
• A monoclonal antibody to the human epidermal growth factor receptor.